Total Payments
$61,523
2024 Payments
$3,446
Companies
16
Transactions
97
Medicare Patients
5,207
Medicare Billing
$364,977
Payment Breakdown by Category
Research$37,730 (61.3%)
Consulting$15,060 (24.5%)
Food & Beverage$5,957 (9.7%)
Travel$2,649 (4.3%)
Education$126.68 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37,730 | 9 | 61.3% |
| Consulting Fee | $15,060 | 5 | 24.5% |
| Food and Beverage | $5,957 | 75 | 9.7% |
| Travel and Lodging | $2,649 | 5 | 4.3% |
| Education | $126.68 | 3 | 0.2% |
Payments by Type
Research
$37,730
9 transactions
General
$23,794
88 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $37,891 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $12,657 | 18 | $0 (2021) |
| Janssen Biotech, Inc. | $5,094 | 11 | $0 (2024) |
| UCB, Inc. | $1,420 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $963.99 | 10 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $588.41 | 6 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $577.71 | 6 | $0 (2022) |
| Lilly USA, LLC | $577.04 | 13 | $0 (2020) |
| Genentech USA, Inc. | $477.70 | 4 | $0 (2019) |
| GENZYME CORPORATION | $477.55 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,446 | 3 | PFIZER INC. ($3,200) |
| 2023 | $7,753 | 4 | PFIZER INC. ($7,720) |
| 2022 | $28,642 | 11 | PFIZER INC. ($26,810) |
| 2021 | $10,565 | 5 | Novartis Pharmaceuticals Corporation ($10,440) |
| 2020 | $1,705 | 9 | Novartis Pharmaceuticals Corporation ($1,606) |
| 2019 | $1,356 | 20 | Lilly USA, LLC ($467.28) |
| 2018 | $6,139 | 26 | Janssen Biotech, Inc. ($4,939) |
| 2017 | $1,918 | 19 | GlaxoSmithKline, LLC. ($407.94) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $123.81 | General |
| 08/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $122.55 | General |
| Category: Immunology | ||||||
| 02/22/2024 | PFIZER INC. | LITFULO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: PF07038124 BREPOCITINIB DAZUKIBART PF06763809 DEKAVIL PF06817024 PF06480605 RITLECITINIB ZIMLOVISERTIB PF06826647 PF06835375 MULTI PRODUCT PF07054894 PF06473871 CLINICAL PUBLICATION PROGRAM • Category: IMMUNOLOGY | ||||||
| 12/08/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $32.58 | General |
| Category: Immunology | ||||||
| 06/02/2023 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: BREPOCITINIB CLINICAL PUBLICATION PROGRAM | ||||||
| 04/05/2023 | PFIZER INC. | — | — | Cash or cash equivalent | $6,450.00 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 01/13/2023 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | ||||||
| 11/16/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $111.40 | General |
| Category: IMMUNOLOGY | ||||||
| 11/02/2022 | PFIZER INC. | — | — | Cash or cash equivalent | $2,420.00 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 11/02/2022 | PFIZER INC. | — | — | Cash or cash equivalent | $1,260.00 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 10/03/2022 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,420.00 | General |
| 09/23/2022 | Kyowa Kirin, Inc. | POTELIGEO (Drug) | Education | In-kind items and services | $12.21 | General |
| Category: Monoclonal Antibody | ||||||
| 09/22/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2022 | PFIZER INC. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 09/13/2022 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $137.78 | General |
| Category: Immunology | ||||||
| 08/17/2022 | PFIZER INC. | — | — | Cash or cash equivalent | $17,903.81 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 08/17/2022 | PFIZER INC. | — | — | Cash or cash equivalent | $4,475.95 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 02/23/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $125.84 | General |
| Category: Immunology | ||||||
| 11/05/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $4,320.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2021 | GENZYME CORPORATION | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $110.26 | General |
| Category: Oncology | ||||||
| 07/17/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $3,960.00 | General |
| Category: IMMUNOLOGY | ||||||
| 04/22/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $2,160.00 | General |
| Category: IMMUNOLOGY | ||||||
| 01/06/2021 | Bausch Health US, LLC | TARGRETIN (Drug) | Education | In-kind items and services | $14.48 | General |
| Category: Oncology | ||||||
| 02/28/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Travel and Lodging | In-kind items and services | $269.70 | General |
| Category: IMMUNOLOGY | ||||||
| 02/28/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $100.64 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | PFIZER INC. | $33,260 | 6 |
| PF07038124 BREPOCITINIB DAZUKIBART PF06763809 DEKAVIL PF06817024 PF06480605 RITLECITINIB ZIMLOVISERTIB PF06826647 PF06835375 MULTI PRODUCT PF07054894 PF06473871 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| BREPOCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 921 | 1,316 | $413,819 | $55,157 |
| 2022 | 18 | 1,023 | 1,469 | $422,155 | $61,264 |
| 2021 | 19 | 990 | 1,423 | $105,518 | $70,087 |
| 2020 | 18 | 2,273 | 3,329 | $293,415 | $178,469 |
Total Patients
5,207
Total Services
7,537
Medicare Billing
$364,977
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 187 | $84,150 | $15,896 | 18.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 177 | 220 | $82,720 | $6,362 | 7.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 77 | $22,792 | $4,731 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $19,089 | $3,341 | 17.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 43 | 48 | $20,948 | $3,137 | 15.0% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 91 | 111 | $42,350 | $3,115 | 7.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 42 | 42 | $18,396 | $2,664 | 14.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 60 | 68 | $20,064 | $2,591 | 12.9% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Office | 2023 | 34 | 34 | $21,930 | $2,544 | 11.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 26 | 27 | $14,823 | $2,327 | 15.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $11,856 | $2,064 | 17.4% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 15 | $10,785 | $1,834 | 17.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 53 | 284 | $15,052 | $1,329 | 8.8% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 28 | 32 | $6,400 | $866.86 | 13.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 11 | 18 | $4,248 | $715.50 | 16.8% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 11 | 22 | $4,290 | $483.90 | 11.3% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2023 | 12 | 22 | $3,806 | $455.22 | 12.0% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 11 | 11 | $2,200 | $297.99 | 13.5% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2023 | 26 | 28 | $4,928 | $249.80 | 5.1% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2023 | 15 | 17 | $2,992 | $151.68 | 5.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 117 | 144 | $64,800 | $12,774 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 139 | 158 | $46,768 | $9,486 | 20.3% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 200 | 264 | $84,706 | $7,686 | 9.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 71 | 73 | $31,532 | $5,412 | 17.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $19,796 | $3,634 | 18.4% |
About Dr. Jason Sluzevich, MD
Dr. Jason Sluzevich, MD is a Dermatology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790751410.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Sluzevich, MD has received a total of $61,523 in payments from pharmaceutical and medical device companies, with $3,446 received in 2024. These payments were reported across 97 transactions from 16 companies. The most common payment nature is "" ($37,730).
As a Medicare-enrolled provider, Sluzevich has provided services to 5,207 Medicare beneficiaries, totaling 7,537 services with total Medicare billing of $364,977. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Jacksonville, FL
- Active Since 02/23/2006
- Last Updated 09/02/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1790751410
Products in Payments
- COSENTYX (Biological) $12,657
- Tremfya (Drug) $5,160
- LITFULO (Drug) $3,200
- NUCALA (Biological) $963.99
- TALTZ (Drug) $556.17
- DUPIXENT DUPILUMAB INJECTION (Biological) $428.87
- DUPIXENT (Biological) $327.59
- TREMFYA (Drug) $292.91
- Erivedge (Biological) $242.23
- Xolair (Biological) $235.47
- EUCRISA (Drug) $160.89
- RHOFADE (Drug) $158.75
- Skyrizi (Biological) $145.98
- LIBTAYO (Biological) $135.56
- STELARA (Biological) $130.03
- Enbrel (Biological) $123.33
- RINVOQ (Biological) $111.40
- Humira (Biological) $109.14
- ATOPIC DERMATITIS - DISEASE (Drug) $76.20
- DUPIXENT (Drug) $62.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Jacksonville
Dr. Pearl Kwong, Md Phd, MD PHD
Dermatology — Payments: $2.8M
Dermatology $2.8M
Michael Bernhardt, Md, MD
Dermatology — Payments: $702,961
Dermatology $702,961
Kristen Stewart, M.d, M.D
Dermatology — Payments: $107,300
Dermatology $107,300
Dr. Douglas Robins, Md, MD
Dermatology — Payments: $24,873
Dermatology $24,873
Jean Mcclintock, Md, MD
Dermatology — Payments: $14,036
Dermatology $14,036
John Morello, M.d, M.D
Dermatology — Payments: $12,575
Dermatology $12,575